Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.
A new player has entered the liquid biopsy game.
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
The latest setback to Bristol-Myers Squibb’s first-line lung cancer plan sees it pull its US filing for Opdivo plus Yervoy.
Full results of the Mystic study present a controversial path forward for Imfinzi, and set the stage for the upcoming Neptune trial to be overhauled.
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.
Cracking the cancer code.